Dat H Tran

7119070, Oct 10, 2006

Apr 30, 2003

10/427715

Michael E. Selsted - Irvine CA, US
Dat Q. Tran - Anaheim CA, US

The Regents of the University of California - Oakland CA

A61K 38/00
A61K 38/01
A61K 38/04
A61K 38/10

514 13, 514 12

The invention provides theta defensin analogs having antimicrobial activity. The invention also provides a method of reducing or inhibiting growth or survival of a microorganism in an environment capable of sustaining the growth or survival of the microorganism, comprising administering an effective amount of a theta defensin analog to the environment, thereby reducing or inhibiting the growth or survival of the microorganism.

7462598, Dec 9, 2008

Aug 29, 2006

11/512883

Michael E. Selsted - Irvine CA, US
Dat Q. Tran - Anaheim CA, US

The Regents of the University of California - Oakland CA

A61K 38/00
A61K 38/01
A61K 38/04
A61K 38/10
C07K 7/00
C07K 7/08

514 13, 514 2, 514 12, 530300, 530326

The invention provides theta defensin analogs having antimicrobial activity. The invention also provides a method of reducing or inhibiting growth or survival of a microorganism in an environment capable of sustaining the growth or survival of the microorganism, comprising administering an effective amount of a theta defensin analog to the environment, thereby reducing or inhibiting the growth or survival of the microorganism.

20080255052, Oct 16, 2008

Jan 7, 2008

12/006991

Michael E. Selsted - Irvine CA, US
Dat Q. Tran - Anaheim CA, US

The Regents of the University of California - Oakland CA

A61K 38/00
A61P 43/00

514 13, 514 14, 514 15

The invention provides a method of inhibiting undesirable microbial contamination, invasion, or growth in an individual by administering to the individual an effective amount of a theta defensin. The invention additionally provides a method of inhibiting deleterious effects resulting from microbial contamination, invasion, or growth in an individual by administering to an individual an effective amount of a theta defensin, whereby immune-mediated pathology is limited and immune function is improved.

20130157964, Jun 20, 2013

Jun 1, 2012

13/486548

Michael E. Selsted - Pasadena CA, US
Dat Q. Tran - Anaheim CA, US

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

A61K 38/12

514 211

Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a θ-defensin, analog or derivative thereof. Inventive methods include researching θ-defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the marketplace for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-α)-converting enzyme (TACE) or other proinflammatory proteases, and/or sheddases. it is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases.

20230072433, Mar 9, 2023

Jul 20, 2022

17/869284

- Los Angeles CA, US
Dat Q. Tran - Alhambra CA, US
Justin B. Schaal - Orange CA, US
Virginia Basso - Covina CA, US

C07K 7/64
A61P 31/00

Novel peptide analogs of a θ-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These novel θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensins.

20230038720, Feb 9, 2023

Sep 20, 2022

17/948904

- Los Angeles CA, US
Dat Q. Tran - Alhambra CA, US
Justin B. Schaal - Orange CA, US

C07K 7/64
A61P 31/00

Peptide analogs of θ-defensins have been developed that are effective in treating multi-drug resistant microbial infections when used at concentrations below those needed to provide a microbicidal effect. These peptides were found to modulate host defense mechanisms to increase clearance of microbial pathogens, enhance phagocytic activity, and enhance neutrophil recruitment while reducing inflammation.

20210403523, Dec 30, 2021

Jun 25, 2021

17/358828

- Los Angeles CA, US
Dat Q. Tran - Alhambra CA, US
Justin B. Schaal - Orange CA, US
Virginia Basso - West Covina CA, US

C07K 14/47

Peptide analogs of a θ-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensins.

20210346463, Nov 11, 2021

Oct 9, 2019

17/283384

Dat TRAN - Alhambra CA, US
Justin SCHAAL - Orange CA, US
Patti TRAN - Alhambra CA, US
Michael E. SELSTED - Pasadena CA, US

A61K 38/12
A61K 47/10

Compositions are provided for formulations of θ-defensin and/or a θ-defensin analog that are highly suitable for parenteral administration. Such formulations provide the θ-defensin and/or a θ-defensin analog in a slightly acidic buffer that includes propylene glycol. Surprisingly, Inventors have found that such formulation increase bioavailability of a θ-defensin and/or a θ-defensin analog so provided by at least a factor of 10 relative to conventional isotonic saline solutions, and that such formulations dramatically improved bioavailability in human subjects relative to animal models. Inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, reducing injection volume permitting sterilization by simple filtration.